Ian Glaspole,1 Francesco Bonella,2 Elena Bargagli,3 Marilyn K Glassberg,4 Fabian Caro,5 Wibke Stansen,6 Manuel Quaresma,7 Leticia Orsatti,7 Elisabeth Bendstrup8
1Department of Allergy, Immunology and Respiratory Medicine, Alfred Health, and Department of Medicine, Monash University, Melbourne, Victoria, Australia; 2Interstitial and Rare Lung Disease Unit, Ruhrlandklinik, University Hospital, Duisburg-Essen University, Essen, Germany; 3Department of Medical Sciences, Surgery and Neurosciences, Siena University Hospital, Siena, Italy; 4Miller School of Medicine, University of Miami, Miami, FL, USA; 5María Ferrer Hospital, Buenos Aires, Argentina; 6Boehringer Ingelheim GmbH & Co. KG, Ingelheim am Rhein, Germany; 7Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany; 8Department of Respiratory Diseases and Allergy, Aarhus University Hospital, Aarhus, Denmark
Introduction
- Patients with IPF frequently have comorbidities that may complicate the course of their disease, impair quality of life and affect adherence to medications.1
- The presence of comorbidities may influence decisions about the use of antifibrotic therapy.
- Nintedanib is an approved treatment for IPF that slows disease progression by reducing decline in forced vital capacity (FVC), with a side-effect profile characterized mainly by gastrointestinal events.2